Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Free Cash Flow (2018 - 2025)

Dna X (SONM) has disclosed Free Cash Flow for 8 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 1169.68% year-over-year to -$7.0 million, compared with a TTM value of -$26.0 million through Sep 2025, down 472.79%, and an annual FY2024 reading of -$8.7 million, down 112.82% over the prior year.
  • Free Cash Flow was -$7.0 million for Q3 2025 at Dna X, down from -$4.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $820000.0 in Q2 2023 and bottomed at -$17.6 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$4.5 million, with a median of -$4.2 million recorded in 2023.
  • The sharpest move saw Free Cash Flow skyrocketed 110.86% in 2022, then plummeted 4751.52% in 2025.
  • Year by year, Free Cash Flow stood at -$17.6 million in 2021, then soared by 87.35% to -$2.2 million in 2022, then surged by 83.69% to -$363000.0 in 2023, then tumbled by 1144.35% to -$4.5 million in 2024, then plummeted by 55.72% to -$7.0 million in 2025.
  • Business Quant data shows Free Cash Flow for SONM at -$7.0 million in Q3 2025, -$4.9 million in Q2 2025, and -$9.6 million in Q1 2025.